Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is roughly 9.11 % above the existing share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the first quarter of 2021.

The present consensus among eleven TipRanks analysts is actually for a reasonable Buy rating of shares in CVS Health, with an average price target of eighty four dolars.

The analysts price targets range from a high of $101 to a low of $61.

From the latest earnings report of its, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net benefit of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The retail or Long Term Care segment has selling of prescription drugs as well as assortment of general merchandise.

The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products and associated services, including medical, pharmacy, dental, behavioural health, healthcare relief abilities. The Corporate segment involves in providing management and administrative services. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Comments are Disabled